Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
机构：[1]Tianjin Med Univ, Dept Thorac Med Oncol, Tianjin, Peoples R China[2]Canc Inst & Hosp, Dept Thorac Med Oncol, Tianjin, Peoples R China[3]Tianjin Med Univ Gen Hosp, Dept Med Oncol, Tianjin, Peoples R China[4]Inner Mongolia Autonomous Reg Peoples Hosp, Dept Med Oncol, Hohhot, Peoples R China[5]First Hosp Shijiazhuang, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China[6]Hebei Univ,Affiliated Hosp,Dept Med Oncol,Baoding,Peoples R China医疗肿瘤内科河北大学附属医院重点学科肿瘤内科
第一作者机构：[1]Tianjin Med Univ, Dept Thorac Med Oncol, Tianjin, Peoples R China[2]Canc Inst & Hosp, Dept Thorac Med Oncol, Tianjin, Peoples R China
推荐引用方式(GB/T 7714)：
Huang D.,Zhong D.,Zhang C.,et al.Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004[J].ANNALS OF ONCOLOGY.2021,32:S969-S969.doi:10.1016/j.annonc.2021.08.1824.
APA：
Huang, D.,Zhong, D.,Zhang, C.,Zhang, Y.,Shang, Y.&Wang, L..(2021).Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004.ANNALS OF ONCOLOGY,32,
MLA：
Huang, D.,et al."Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004".ANNALS OF ONCOLOGY 32.(2021):S969-S969
医学